am-6545 am-6545 am-6545 is a drug which acts as a peripherally selective silent antagonist for the cb1 receptor, and was developed for the treatment of obesity. other cannabinoid antagonists such as rimonabant have been marketed for this application, but have subsequently been withdrawn from sale because of centrally mediated side effects such as depression and nausea. because am-6545 does not cross the blood–brain barrier to any significant extent, it does not produce these kinds of side effects, but has still been shown to effectively reduce appetite and food consumption in animal studies. am-6545identifiers iupac name 5-(4-phenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(1,1-dioxo-thiomorpholino)-1h-pyrazole-3-carboxamide cas number1245626-05-4 npubchem cid46912919chemspider26333263 ycomptox dashboard (epa)dtxsid70677329 echa infocard100.216.518 chemical and physical dataformulac26h23cl2n5o3smolar mass556.46 g·mol−13d model (jsmol)interactive image smiles o=s4(=o)ccn(cc4)nc(=o)c1nn(-c2ccc(cl)cc2cl)c(c1c)-c3ccc(c#cccc#n)cc3 inchi inchi=1s/c26h23cl2n5o3s/c1-18-24(26(34)31-32-13-15-37(35,36)16-14-32)30-33(23-11-10-21(27)17-22(23)28)25(18)20-8-6-19(7-9-20)5-3-2-4-12-29/h6-11,17h,2,4,13-16h2,1h3,(h,31,34) ykey:xbhqlfvdglpbck-uhfffaoysa-n y ny (what is this?)